Navigation Links
Misonix Announces New Distribution Agreement for Portugal
Date:4/13/2009

FARMINGDALE, N.Y., April 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Ekrior Lda, a Division of Avanco Sistemas Medicos, based in Barcarena, Portugal, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator, the BoneScalpel(TM) Ultrasonic Bone Cutter, and the SonicOne(R) Ultrasonic Wound Debrider. The agreement provides Ekrior with the rights to sell in Portugal, and includes minimum purchase requirements.

Ekrior is growing rapidly in the Portuguese market, largely by building a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis on radiation oncology and specialized surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
2. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
3. Misonix Announces New Sales Agency Agreement for Eastern Europe
4. Misonix Announces New Distribution Agreement for Israel
5. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
6. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
7. Misonix Announces New HIFU Distribution Agreement for Italy
8. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
9. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
10. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
11. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation ... , ... (PRWEB) ... Annual Midyear Clinical Meeting of the American Society of ... with RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation ...
(Date:12/7/2009)... -- UCB today announced new findings on its ... evidence supporting the use of this AED as ... Results of presented research demonstrate sustained efficacy ... up to three years, and a consistent long-term ... adverse events potentially related to cognition occurred at ...
(Date:12/7/2009)... protect their children and grandchildren from a dismal ... prepared to make the difficult choices necessary to ... ,, This becomes clear in a report released ... year of its Fiscal Stewardship Project. Supported by ... the project established six advisory councils around the ...
(Date:12/7/2009)... Dec. 7 Results of two new ... of the antiepileptic drug (AED) Vimpat® for patients ... AED therapy is temporarily not feasible. These ... 63rd annual meeting of the American Epilepsy Society ... Vimpat in the institutional setting. ,, One study ...
(Date:12/7/2009)... LOS ANGELES, Dec. 7 Stand Up ... awarding $9.68 million to support high-risk/high-reward cancer research ... period, each investigator will receive a total of ... Research Grants program, which supports the next generation ... ) ,, "We asked our best and brightest ...
Breaking Medicine News(10 mins):Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9
... This release is also available in <A HREF="http://www.eurekalert.org/pub_releases_ml/2008-08/aaft-t080108.php,">German . ... of their face might change, but they don,t immediately ... it as a third leg. With some molecules, however, ... a gold cluster with seven atoms. In a charged ...
... offered to employees and spouses for completion of health risk assessment resulted ... , ... Minneapolis, MN (PRWEB) August 1, 2008 -- Employers are increasingly ... productivity programs. A new issue brief from HealthFitness (OTC BB: HFIT) ...
... national leader in the document scanning industry, announced ... online at http://www.imagedocusa.com . The site ... initiative inviting businesses to "Go Paperless!" ImageDoc ... conversion services and has created a reputation as ...
... that cannabinoid cell surface receptor CB1 plays a tumor-suppressing ... Aug. 1 edition of the journal Cancer Research ... nausea, elevating mood and stimulating appetite by serving as ... molecules. It now may serve as a new path ...
... Web video and audio for this news release are posted ... and audio are,also available in high resolution for TV broadcast ... for the marathon continues to improve for both men and ... about as fast as the record pace,for the 10,000-meter run ...
... MIGDAL HA,EMEK, Israel, July 31 ACS Motion,Control Ltd., ... motion control products, reports second quarter revenues and,earnings., ... compared to,$2,149,000 in the second quarter of 2007. Revenues ... to $4,570,000 revenues reported in the,first six months of ...
Other Medicine News:Health News:Nano sculptures in gold 2Health News:Nano sculptures in gold 3Health News:Nano sculptures in gold 4Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 2Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 3Health News:ImageDoc USA, Inc. Launches "Go Paperless!" Website 2Health News:Turned-off cannabinoid receptor turns on colorectal tumor growth 2Health News:Turned-off cannabinoid receptor turns on colorectal tumor growth 3Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 2Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 3Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 4Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 5Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 6Health News:Mayo Clinic on the Summer Olympic Games: Better Athletes, the Physiology of Performance, the Lactate Threshold, the Aging Athlete and Much More 7Health News:ACS Motion Control Ltd. Reports Second Quarter Results 2Health News:ACS Motion Control Ltd. Reports Second Quarter Results 3Health News:ACS Motion Control Ltd. Reports Second Quarter Results 4
(Date:12/4/2009)... BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a ... today announced the initial development and successful testing of ... Axsun believes this proprietary optical engine design raises ... of laser-based designs for swept source OCT light sources. ...
(Date:12/4/2009)... Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an ... and Drug Administration seeking approval to market its 8mg ... owned by Takeda Pharmaceutical Company Limited. Watson,s 8mg ...
(Date:12/4/2009)... Neal Shore and E. David Crawford presented results for ... secondary end points of biochemical recurrence rate in a ... injection) or monthly leuprolide in prostate cancer patients during ... who received FIRMAGON 240/80 mg/month had a recurrence rate ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 1Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 2Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office 55116 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 1School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 2School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 3School Nurses Tackle Low Parental Awareness of Meningitis Via Comprehensive National Public Education Campaign 55114 4Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 1Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 13658 2
... CR011-vcMMAE for ... melanoma -, - Preliminary Phase I/II results to be presented in June ... ... CRGN ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has ...
... ORENCIA is a First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) ... (NYSE: BMY ) today announced that the U.S. Food ... symptoms in pediatric patients six years and older with moderately ...
Other Medicine Technology:CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Medicine Products: